Noskapin Dak (Noscapine Hydrochloride)

Noscapine Hydrochloride, the active ingredient in Noskapin Dak, is an antitussive presented as an oral formulation for oral use. It is employed to suppress coughing episodes, particularly dry or non‑productive coughs, in adult patients, working centrally to reduce the cough reflex without narcotic effects.

GNH USA supplies Noskapin Dak as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution. The product is manufactured under EU GMP guidelines to ensure consistency and safety.

Noskapin Dak, containing noscapine hydrochloride, acts on the central cough pathway to provide symptomatic relief of cough.

- Dry cough: reduces frequency and intensity of non‑productive cough episodes - Upper respiratory tract irritation: alleviates cough associated with throat irritation - Post‑viral cough: helps control lingering cough after viral infections

Noskapin Dak may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset may occur - Dizziness: transient light‑headedness reported - Drowsiness: occasional sedation - Headache: mild headache may be experienced

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing - Hepatic dysfunction: elevated liver enzymes or jaundice - Severe hypotension: sudden drop in blood pressure

When prescribing Noskapin Dak, clinicians should consider the following precautions to ensure safe use.

- Pregnancy: safety has not been established; avoid unless benefits outweigh risks - Breastfeeding: unknown excretion in milk; use with caution - Renal impairment: dose adjustment may be required in severe kidney dysfunction - Concomitant CNS depressants: may enhance sedative effects - Hypersensitivity: discontinue if allergic reaction occurs - Store at ambient temperature: keep in original packaging, protect from moisture and light

Noskapin Dak can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - CYP3A4 inhibitors: may increase noscapine plasma concentrations - CNS depressants: additive sedation or respiratory depression - Anticoagulants: potential enhancement of bleeding risk

Moderate Interactions (Monitor Closely): - Antihistamines: may potentiate antitussive effect - Other antitussives: risk of excessive cough suppression